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Abstract
Background:  Microarray-based gene expression profiling is a powerful approach for the
identification of molecular biomarkers of disease, particularly in human cancers. Utility of this
approach to measure responses to therapy is less well established, in part due to challenges in
obtaining serial biopsies. Identification of suitable surrogate tissues will help minimize limitations
imposed by those challenges. This study describes an approach used to identify gene expression
changes that might serve as surrogate biomarkers of drug activity.
Methods: Expression profiling using microarrays was applied to peripheral blood mononuclear cell
(PBMC) samples obtained from patients with advanced colorectal cancer participating in a Phase III
clinical trial. The PBMC samples were harvested pre-treatment and at the end of the first 6-week
cycle from patients receiving standard of care chemotherapy or standard of care plus SU5416, a
vascular endothelial growth factor (VEGF) receptor tyrosine kinase (RTK) inhibitor. Results from
matched pairs of PBMC samples from 23 patients were queried for expression changes that
consistently correlated with SU5416 administration.
Results: Thirteen transcripts met this selection criterion; six were further tested by quantitative
RT-PCR analysis of 62 additional samples from this trial and a second SU5416 Phase III trial of
similar design. This method confirmed four of these transcripts (CD24, lactoferrin, lipocalin 2, and
MMP-9) as potential biomarkers of drug treatment. Discriminant analysis showed that expression
profiles of these 4 transcripts could be used to classify patients by treatment arm in a predictive
fashion.
Conclusions: These results establish a foundation for the further exploration of peripheral blood
cells as a surrogate system for biomarker analyses in clinical oncology studies.
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Background
Identification of biomarkers that provide rapid and acces-
sible readouts of drug exposure, activity, toxicity or effica-
cy is becoming increasingly important in the clinical
development of novel molecularly targeted therapeutics.
Surrogate endpoints can be applied in the assessment of
biological activity or clinical responses and perhaps in se-
lection of patients most likely to respond to therapy.
Methodologies for large-scale molecular profiling of dis-
ease tissues have been well established [1–3] and have
been shown to be of utility both diagnostically [4] and
prognostically [5]. However, application of such ap-
proaches in the assessment of changes induced by cancer
therapeutic agents in solid tumors in man has been hin-
dered by limited accessibility or availability of tumor tis-
sue at multiple time points during treatment. We
evaluated the utility of patients' blood cells, a readily ac-
cessible source of material, for the identification of surro-
gate molecular markers of biological activity of SU5416, a
small molecule kinase inhibitor that is a VEGF receptor
(VEGFR) antagonist with anti-angiogenic properties in
vitro and in vivo[6,7].
Microarray technologies such as the Affymetrix Genechip®
platform facilitate rapid measurement of the expression
levels of thousands of transcripts in a single experiment
and allow comparison of expression patterns across many
samples [8]. Previous reports have described gene expres-
sion profiles in blood that distinguish patients with re-
lapsing-remitting multiple sclerosis [9] and systemic
lupus erythematosus [10] from healthy controls. We fo-
cused on blood cell samples from oncology clinical trials
that evaluated SU5416 in patients with metastatic colorec-
tal cancer. We reasoned that peripheral blood cells may
serve as a surrogate tissue since VEGF receptors are ex-
pressed in certain blood cell types such as monocytes and
platelets [11,12] and thus signal transduction in those
cells may be directly impacted by SU5416; also, gene ex-
pression changes in blood cells caused indirectly as a re-
sult of therapy-induced perturbations might also be
detected in this approach.
Subjects in the initial investigation were participants in an
open-label, multicenter, international Phase III study in
which patients were randomized to be treated with either
the standard-of-care 5-FU/LV chemotherapy (control
arm) regimen alone or 5-FU/LV chemotherapy co-admin-
istered with SU5416 (treatment arm) administered twice
weekly via intravenous infusion at a dose of 145 mg/m2
(for more detail see [13,14]). Affymetrix expression profil-
ing technology was applied to RNA from matched periph-
eral blood mononuclear cell (PBMC) sample pairs (before
and after treatment) harvested from subjects, for assess-
ment of changes in gene expression that might correlate
with SU5416 administration. Here we describe the ap-
proach and summarize key findings from the study as well
as some of the practical challenges that were encountered.
A set of transcripts that correlated with administration of
the SU5416 regimen was identified and independently
validated in additional clinical samples; discriminant
analysis of change in levels of these transcripts demon-
strated their potential utility in class prediction. The im-
plications of gene expression profiling applications such
as this one in the clinical development of novel molecular
therapies are discussed.
Methods
Study population
Patient samples were derived from 2 randomized, open-
label, multicenter Phase III clinical trials comparing
standard of care chemotherapy alone or combined with
SU5416 in patients with metastatic colorectal cancer. In
both trials SU5416 was delivered twice weekly at a dose of
145 mg/m2 via I.V. infusion. In the first trial (designated
Trial A), the standard of care chemotherapy consisted of
weekly administration of 5-FU and leucovorin (Roswell
Park regimen); in the second trial (designated Trial B), the
standard of care chemotherapy consisted of weekly or bi-
weekly administration of 5-FU, leucovorin, and Irinote-
can (CPT-11). A total of 23 pairs of patient samples were
included in Affymetrix microarray expression profiling
analysis (2 females and 9 males in the SU5416 treatment
arm, and 2 females and 10 males in the control arm). The
median patient age was 66 and 65 years for the SU5416
treatment arm and control arm, respectively. For RT-PCR
verification experiments, samples from 12 females and 24
males from the SU5416 treatment arm, and 14 females
and 17 males from the control arm were used. The median
age for these patients was 62 and 60 years, respectively.
Clinical response criteria were defined according to RE-
CIST guidelines; briefly, complete response (CR) is de-
fined as complete disappearance of all measurable and
evaluable clinical evidence of cancer; partial response
(PR) is defined as at least a 50% reduction in the size of
all measurable tumor areas, progressive disease (PD) is
defined as an increase of ≥25% (compared to baseline or
best response) in the size of all measurable tumor areas;
and stable disease (SD) is defined as neither sufficient
shrinkage to qualify for PR nor sufficient increase to qual-
ify for PD
Patient samples
All clinical samples for biomarker analysis were harvested
and handled in accordance with full Institutional Review
Board-approved protocol, and study participants had
signed the study informed consent prior to any study-re-
lated procedures. All blood samples were collected into
Vacutainer tubes containing sodium heparin. Ten ml of
blood was withdrawn from patients prior to receiving any
treatment on day 1 and also prior to dosing at end of cycleBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/3
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1 (day 56 in Trial A, day 42 in Trial B). For PBMC prepa-
rations, blood samples were shipped overnight at ambient
temperature to a central processing facility (Quest Diag-
nostics, Inc., Collegeville, PA, USA) for PBMC isolation
via Ficoll gradient method [15]. Purified PBMCs were
shipped in RNA lysis buffer (Clontech, Palo Alto, CA,
USA) to SUGEN where isolation of total RNA was per-
formed. For Trial B, whole peripheral blood samples were
directly frozen at the clinical sites and shipped on dry ice
to SUGEN for RNA isolation.
RNA sample processing
Total RNA was purified from PBMC samples using Clon-
tech Nucleospin RNA II kit reagents (Clontech, Palo Alto,
CA) and from whole blood samples using MRC TRI Rea-
gent BD (Molecular Research Center, Cincinnati, OH,
USA), an adaptation of the Chomczynski single-step
method [16], according to the manufacturer's instruc-
tions. All sample preparations included a treatment with
RNAse-free Dnase. RNA yields were measured by UV ab-
sorbance and RNA quality was assessed by agarose gel
electrophoresis with ethidium bromide staining for visu-
alization of ribosomal RNA band integrity.
Affymetrix high-density oligonucleotide microarray analy-
sis of PBMC expression profiles
In general, the standard RNA processing and hybridiza-
tion protocols as recommended by Affymetrix (Santa
Clara, CA, USA) were followed in this study; these proto-
cols are available in the Genechip® Expression Analysis
Technical Manual. Yields of total RNA for PBMC samples
were generally low and for the majority of patients it was
not possible to use the standard amount of total RNA (≥
5 µg) as recommended in the standard protocol. There-
fore a double linear amplification approach [17] was used
in the generation of cRNA for hybridization. In these ex-
periments, equal amounts of starting material were used
for pre- and post-treatment samples from each donor
(typically 2 µg). Briefly, the protocol was as follows: dou-
ble-stranded cDNA was synthesized from total RNA, with
Invitrogen Life Technologies SuperScript Choice system
reagents (Invitrogen, Carlsbad, CA, USA). The T7-(dT)24
oligomer was used for priming first-strand cDNA synthe-
sis. Double-stranded cDNA product was purified via phe-
nol-chloroform extraction, and then used as template in
first round of in vitro transcription (IVT) of cRNA. The IVT
reaction was performed with BioArray HighYield RNA
Transcript Labeling Kit (Affymetrix) according to manu-
facturer's protocol, but with substitution of non-bioti-
nylated ribonucleotides for biotinylated ribonucleotides.
The cRNA product was then purified with Qiagen spin col-
umn clean-up protocol and used as template in second
round of cDNA synthesis. This second round of cDNA
synthesis was similar to the first round except that random
hexamers were used in priming of first-strand synthesis,
with T7-(dT)24 oligomer priming the second-strand. The
second round of IVT of cRNA was as in the first round but
with biotinylated ribonucleotides rather than non-bioti-
nylated ribonucleotides. Purified cRNA was quantitated,
chemically fragmented according to Affymetrix protocol,
and then hybridized overnight on Human Genome U95A
Arrays (which contain probe sets for the detection of ap-
proximately 12,600 transcripts). Hybridized arrays were
washed and stained with phycoerythrin-conjugated
streptavidin detection chemistry in an Affymetrix Fluidics
station. Images were scanned with a Hewlett-Packard Ge-
neArray scanner.
Data Analysis
Data files were generated from scanned array images in
the Affymetrix Microarray Suite Version 4.0 program. In
this program, Average Difference (AD) values serve as rel-
ative indicators of the expression level of transcripts repre-
sented on the arrays. Average Difference determination
relies on difference between background-subtracted signal
from perfect match (PM) oligos and corresponding mis-
match control (MM) oligos within a probe set represent-
ing a given transcript. To enable comparison of all
hybridization data, global scaling was applied by multi-
plying the output of each experiment by a Scaling factor
(SF) to make its average intensity equal to a user-defined
Target Intensity (which was set at 1500 for these experi-
ments). For comparisons between time points from a sin-
gle patient, batch files were generated with Microarray
Suite. These files contain calculated fold change (FC) val-
ues, which represent differential expression between day
56 compared to baseline, and also Difference Calls (DC),
which represent a more conservative estimate of differen-
tial expression, with qualitative scores assigned to each
transcript measurement according to the following sys-
tem: Increased (I), Marginally Increased (MI), No Change
(NC), Marginally Decreased (MD), and Decreased (D).
Subsequent data analysis was performed primarily with
Spotfire DecisionSite for Functional Genomics software
(version7.0) package and its Array Explorer component
(Spotfire, Somerville, MA). Hierarchical clustering analy-
sis and statistical comparisons were included in this step.
Further refinement of the data, including filtering by Dif-
ference Call scores, was done with the Microsoft Access 97
database analysis program.
SYBR Green quantitative RT-PCR verification of array 
results
Primers were designed with Primer Express 1.5 software
(Applied Biosystems). In all cases, primers were designed
to bind within the sequence represented by Affymetrix
probe sets (target sequence information available at http:/
/www.affymetrix.com/analysis/index.affx). Total RNA
samples (1 µg) were reverse transcribed to yield first-BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/3
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strand cDNA using the Applied Biosystems Reverse Tran-
scription Reagents protocol (Applied Biosystems, Foster
City, CA, USA). The reverse transcription reactions were
then diluted 1:5 in distilled H2O. SYBR Green PCR reac-
tions were performed in 96-well optical plates and run in
an ABI PRISM® 7700 Sequence Detection System (SDS)
machine. For individual reactions, 10 µl of each sample
were combined with 15 µl of SYBR Green PCR Master Mix
(Applied Biosystems) containing the appropriate primer
pair at 350 nM. Data were extracted and amplification
plots generated with ABI SDS software. All amplifications
were done in duplicate and threshold cycle (Ct) scores
were averaged for subsequent calculations of relative ex-
pression values. The Ct scores represent the cycle number
at which fluorescence signal (∆Rn) crosses an arbitrary
(user-defined) threshold. Heat dissociation curve analysis
was performed after each SYBR Green run as a test of
whether a single product had been generated in each PCR
reaction; multiple peaks in the dissociation curves are in-
dicative of multiple PCR products and thus reduced spe-
cificity and sensitivity.
Quantitation and statistical analysis of SYBR Green RT-
PCR data
The Ct scores for genes of interest for each sample were
normalized against Ct scores for the corresponding endog-
enous control gene, which was the β-glucuronidase (GUS)
gene. Relative expression for day 56 compared to day 1
was determined by the following calculation, as described
in the Applied Biosytems users bulletin on Relative Quan-
titation of Gene Expression and in [18]:
Rel Exp = 2-∆∆Ct,
Where ∆∆ Ct = (Ct Target - Ct GUS)day 56 - (Ct Target - Ct
GUS)day 1.
The relative expression data for a selected subset of poten-
tial biomarkers were tested for differences between the
SU5416 (treatment) and the standard of care (control)
arms. The Mann-Whitney U Test with a critical alpha level
of 0.05 was used for statistical significance. Individual
genes observed to be significantly different by Affymetrix
analysis and in both sets of SYBR Green RT-PCR experi-
ments were screened as potential biomarker candidates.
This subset of potential biomarker candidates was tested
subsequently for utility as class predictors to discriminate
between the SU5416 and the standard of care arms. Dis-
criminant analysis [19], a multivariate statistical tech-
nique, was used for this purpose. The genes were tested
individually, using all possible combinations, and by re-
ducing dimensions (Principal Component Analysis) in
order to determine the subset of genes (predictor varia-
bles) that yielded highest classification accuracy. Cross-
validation was used to test the robustness of classification
accuracy. Results from three different cross-validations
were evaluated to select the best set of predictor biomark-
ers: (1) jackknife method (dropping one case at a time),
(2) randomly splitting the pooled data into two halves,
prediction (for building model) and validation (for test-
ing model) sets, and (3) using one trial as prediction and
the second trial as validation sets, respectively. All statisti-
cal analyses were carried out after natural-log transforma-
tion of the data; SYSTAT 9.01 (SPSS, Inc., Chicago, IL,
USA) software was used in statistical analysis.
Results
Affymetrix expression profiling of pre- and post-treatment 
matched PBMC samples
Total RNA was isolated from PBMC prepared from pa-
tient's blood samples taken before (pre-dose day 1) and
after (pre-dose day 56) administration of SU5416 or cor-
responding control regimen in a Phase III trial, designated
as Trial A. Due to typically low RNA yields, many sample
pairs were of insufficient quality for further use (failure
rate of at least 1 of 8 samples, or 25% of sample pairs).
Only sample pairs in which both day 1 and day 56 sam-
ples RNA yields were of 1 µg or greater were used in ex-
pression profiling analysis. Samples were hybridized to
U95A high-density oligonucleotide arrays. A total of 11
sample pairs from the SU5416 treatment arm and 12 from
the control arm were analyzed in the primary dataset. The
change in expression (ratio of day 56 measurements to
day 1 for each patient as calculated by Affymetrix soft-
ware) was defined for each transcript; these are referred to
as fold change (FC) values. The FC values for the 23 cases
were analyzed with Spotfire Decision Site software tools,
to compare patients in the SU5416 arm and control arm.
A t-test analysis was used to identify transcripts that were
statistically significantly different between the two treat-
ment arms. Over 100 genes with p-values less than 0.02
were identified; however, because there are over 12,000
transcripts measured on the U95A arrays, some of the
genes would potentially be identified by chance. To fur-
ther refine this subset of genes, queries based on Differ-
ence Call (DC) status were performed; Difference Calls
offer a more stringent but non-numerical measure of dif-
ferential expression, and are derived from a decision ma-
trix that weighs comparison results from four metrics used
in the Affymetrix analysis platform. The data were filtered
to identify genes that were 'Increased' (I) or 'Decreased'
(D) in a majority of the SU5416 arm cases but not in the
control arm. A group of 13 genes that frequently showed
increased expression was identified. Figure 1 displays a
schema of the DC scores assigned to each gene for each
patient sample pair; all cases from the SU5416 arm show
induction in at least 6 of the 13 genes. Table 1 lists the
number of cases in each arm in which an 'Increased' call
was assigned and includes a brief description of putativeBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/3
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Figure 1
Differential expression of candidate biomarker transcripts in patient PBMC at day 56 relative to day 1 of therapy. The diagram 
is a depiction of the Affymetrix Difference Calls assigned to each day 56:day 1 expression comparison among the patient sam-
ple pairs analyzed via GeneChip hybridization analysis. Letters within blocks represent the Difference Call assigned to each rel-
ative expression comparison. The abbreviations are: I = Increase, MI = Marginally Increased, NC = Not changed; MD = 
Marginally Decreased; D = Decreased. Cases in which an Increased or Marginally Increased call is assigned to a day 56:day 1 
comparison are shaded in gray. Each column represents a different patient. Column headings in each grid represent patient 
response assessed at end of first treatment cycle: PR = partial response, CR = complete response, PD = progressive disease.
Table 1: List of potential biomarker transcripts as detected in Affymetrix analysis.
Affymetrix probe 
set ID number
Gene name/symbol Putative function(s) Increased in 
5416 arm
Increased in 
Control arm
34546_at Defd Defensin α 4 Corticostatic, Ca channel regulator 10 6
33530_at CEA CAM 8 Tumor antigen, integral membrane protein. 9 4
37054_at BPI Anti-pathogen response 9 4
31859_at MMP-9 Protease; ECM maintainence 8 2
32821_at Lipocalin 2 Anti-pathogen response; apoptosis 10 5
34319_at S100 P Ca-binding protein 9 3
41249_at Hypothetical protein FLJ13052 unknown 7 1
1962_at Liver arginase Amino acid metabolism 9 3
266_s_at CD24 antigen Anti-pathogen response; differentiation of B cells 9 0
31506_s_at Defensin α 3 Chemotaxis; anti-microbial response 10 4
32275_at Antileuko-protease Secreted inhibitor of serine proteases 9 4
115_at Thromobospondin 1 Blood clotting; angiogenesis 9 3
37149_s_at Lactoferrin Iron transport; putative protease 11 5
A brief summary of putative biological function is listed for each gene product. The ID number assigned by Affymetrix to each transcript-specific 
probe set is also included. The last two columns list the number of patients in which transcript levels were increased at day 56 relative to day 1; 
total number of patients it 11 for the SU5416 arm and 12 for the control arm.
SU5416 Arm Control Arm
PR PR PR PR PR PR PD PD PD PD PD CR PR PR PR PR PR PD PD PD PD PD PD
Defensin α α α α 4 I I I I I I I I I I NC NC NC NC NC I NC I I I I I NC
CEA CAM 8 I I N CI I I I I I I N C N CN CN CN CI N CI N CI N CI N C
BPI IIN C IIIIIIIN C N C N C N C N C N C N C IIIN C IN C
MMP-9 I I NC I I I I I NC I NC I D NC D NC D NC D D NC I D
Lipocalin 2 IIN C IIIIIM I II N C D N C N C IN C IIIN C IN C
S100 P IN C IIIIIIIIN C ID N C D ID N C N C N C N C ID
Hypothetical protein FLJ13052 NC NC NC I I I I I D I I NC D NC D NC NC NC D D NC I NC
Liver arginase I I NC I I I I I I I NC I NC NC NC NC D I NC NC MI I NC
CD24 antigen I I N CI I I I I I I N C N CN CN CN CN CN CN CN CN CN CN CN C
Defensin α α α α 3 M I IIM I IIN C IIII D N C ID N C IN C N C IN C IN C
Antileuko-protease I I NC I I NC I I NC I I NC NC I NC I NC NC NC I NC I D
Thromobospondin 1 I I I MD I NC I I I I I NC D NC D NC NC I I MI NC NC NC
Lactoferrin IIIIIIIIIII N C D ID IN C IN C IN C IDBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/3
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functions of the gene products. The average fold change of
all of these transcripts was higher in the SU5416 arm (the
lowest average fold change was 2.6 for hypothetical pro-
tein FLJ13052, the highest was 33 for lactoferrin); the
range of fold changes was also broader in this category,
presumably reflecting variability among patients.
Quantitative RT-PCR validation of differentially expressed 
transcripts
A subset of these transcripts was chosen for validation by
quantitative RT-PCR (qRT-PCR) analysis. Primer sets were
designed for 6 of the 13 genes; matrix metalloproteinase-
9 (MMP-9), thrombospondin-1 (TSP-1), CD24, defensin
α3, lipocalin-2 (LNC2), and lactoferrrin (see Table 2).
These 6 genes were chosen based on potential functions of
encoded proteins (in the cases of thromobospondin 1 and
MMP-9, these have known roles in angiogenesis) [20,21],
or because of the extent of differential regulation between
treatment arms. Also, the lipocalin-2 gene (LCN2) has
been reported to be inducible by dexamethasone in
murine cells [22]; dexamethasone is one of the premedi-
cations administered to patients in the SU5416 arm.
SYBR Green RT-PCR was used to validate the microarray
expression profiling data. SYBR Green is a dye that fluo-
resces when bound to double-stranded DNA, thus signal
is directly proportional to the amount of product formed
during PCR amplification [18,23]. This method allows
rapid and inexpensive comparison of gene expression
across a large number of samples. The qRT-PCR validation
was performed with a total of 31 sample pairs, 8 of which
had previously been analyzed on Affymetrix U95A arrays
and thus allowed a direct comparison of the correlation-
between the 2 transcript profiling methods. Data for each
gene was normalized to expression of a housekeeping
gene, β-glucuronidase (GUS). Direct comparison of SYBR
Green RT-PCR results and Affymetrix results from the
same RNA samples (n = 8 day 1-day 56 pairs) showed an
overall qualitative agreement (i.e., same trend of induc-
tion or no change detected by both methods for each tar-
get) of 73%, as 35 of 48 comparisons were concordant.
This number may be an underestimate since results for
one patient were inconsistent for all 6 transcripts.
Figure 2 summarizes the results from the RT-PCR valida-
tion and compares them to those from Affymetrix analy-
sis. Mann-Whitney U test comparison of SU5416 and
control results from both analyses indicates that three of
the six genes displayed statistical significance (p-values
less than 0.05) based on the SYBR Green RT-PCR data (Ta-
ble 3); these are CD24, lactoferrin, and LCN2. MMP-9 ex-
hibited a p-value that was close to the significance cutoff
and thus was also selected for further analysis. Defensin
α3 and TSP-1 were not pursued further. Thus, four of the
six initial transcripts selected from Affymetrix expression
profiling were confirmed as differentially expressed using
a PCR-based approach, in a larger sample set from the
same clinical trial.
Quantitative RT-PCR validation of differentially expressed 
transcripts with samples from a second Phase III SU5416 
trial
To further confirm these transcripts as potential biomark-
ers of SU5416 administration, SYBR Green RT-PCR analy-
sis was carried out in samples from a second Phase III trial
using SU5416 (Trial B). This trial was also a randomized
metastatic colorectal cancer study, comparing a new
chemotherapy standard of care, 5-FU/leucovorin/CPT
[24,25] to standard of care plus SU5416. RNA was isolat-
ed from patients' peripheral blood samples (rather than
PBMC) harvested at the beginning (pre-dose day 1) and
end (day 42) of cycle 1. In order to test if similar gene
expression changes occurred, analysis was performed on
36 sample pairs, 18 from SU5416 treatment arm and 18
from control arm.
Figure 3 summarizes the overall frequency of induction of
2-fold or greater in each arm of the trial. It is clear that
these transcripts are more frequently induced at day 42 of
treatment in the SU5416 arm than in the control arm.
This is supported by statistical analysis, as indicated in re-
sults of the Mann-Whitney U Test (Table 4). A visual
representation of hierarchical clustering analysis of the
Table 2: Primer sequences used in RT-PCR validation
Transcript Forward Primer Reverse Primer
Thrombospondin 1 TTGGCTACCAGTCCAGCAGC GGGTTGGTGTCCCAGTAGGA
MMP-9 CCCGGAGTGAGTTGAACCA CCTAGTCCTCAGGGCACTGC
Defensin α3 CCCAGAAGTGGTTGTTTCCCT GTCCATGTTTTTCCTTGAGCCT
Lactoferrin CTGGAAGCCTGTGAATTCC GAATGGCTGAGGCTTTCTTGG
Lipocalin-2 GCTGACTTCGGAACTAAAGGAGAA TGGGACAGGGAAGACGATGT
CD 24 CTGCCTCGACACACATAAACCTT CATCTAAGCATCAGTGTGTGACCABMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/3
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qRT-PCR relative expression values from both trials for
the each of the transcripts is displayed in Figure 4. This
clustering pattern displays the distinction between the
SU5416 and control arms based on relative expression da-
ta, and also indicates further distinctions among subsets
of patients as well as the degree of overlap between trial
arms in the clustering pattern. The extent of similarity be-
tween the relative expression patterns for each transcript
(represented in columns) is also indicated; the pattern of
MMP-9 is distinct from the others as it appears in a sepa-
rate branch in the dendrogram structure. A table contain-
ing the raw relative expression measurements included in
this dataset can be viewed in Additional file 1 .
Figure 2
Differential expression of 6 transcripts as measured by 
microarray and quantitative RT-PCR. The percentage of 
cases in 5-FU/LV (control) and 5-FU/LV + SU5416 trial arms 
with increased expression (at predose day 56 relative to pre-
dose day 1) of each transcript is displayed. Panel A displays 
results from Affymetrix analysis and Panel B displays results 
from SYBR Green RT-PCR verification. For the Affymetrix 
data, an increase is determined by Difference Call status; for 
the SYBR Green data, an increase is defined here as relative 
expression value of 2-fold or greater. A total of 31 sample 
pairs were used in RT-PCR analysis; 18 were from SU5416 
arm (5 PR, 1 CR, 11 PD, and 1 SD response at end of cycle 
1), and 13 were from the control arm (9 PR, 3 PD, and 1 SD). 
The relative expression values as determined in the RT-PCR 
analysis for each patient are displayed (see Additional File 1).
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Table 3: Mann-Whitney U Test comparisons of expression fold 
changes from SU5416 treatment and control arms (Trial A).
P-value of Mann-Whitney U Test
Gene Affymetrix SYBR Green RT-PCR
(n = 23) (n = 31)
MMP-9 0.0025 0.0748
Thrombospondin 1 0.0267 0.7186
CD24 0.0006 0.0057
Defensin α 3 0.0002 0.2196
Lactoferrin 0.0002 0.0065
Lipocalin 2 0.0005 0.0057
Separate comparisons were performed on expression change values 
(predose day 56: predose day 1 ratios) from Affymetrix analysis and 
from SYBR Green RT-PCR validation experiments. P-values ≤ 0.05 
were considered significant.
Figure 3
Differential expression of four transcripts in a second Phase 
III trial as measured by quantitative RT-PCR. Percentage of 
cases in CPT-11/5-FU/LV (control) and CPT-11/5-FU/LV + 
SU5416 trial arms with increased expression (at predose day 
42 relative to predose day 1) of 4 candidate biomarker tran-
scripts in a second SU5416 Phase III clinical trial is displayed. 
The convention is the same as in panel B in Figure 2. A total 
of 36 sample pairs was included in this analysis; 18 from the 
SU5416 arm and 18 from the control arm (8 PR and 10 SD 
responses at end cycle 1 in each group). The relative expres-
sion values for each patient in this group are displayed (see 
Additional File 1).
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Figure 4
Hierarchical clustering of relative expression ratios for four biomarker transcripts. This mosaic depicts association between 
patient samples and relative expression of the 4 potential biomarker transcripts. Natural log-transformed SYBR Green RT-PCR 
ratio data (relative expression of day 56: day 1) were used in analysis. In the color scheme, higher ratios are indicated in red, 
lower ones in green (scale ranges from -4 to +4). Results from individual patients are oriented as rows and transcripts are ori-
ented as columns. Red bars on the right side of the map indicate cases from the SU5416 arm. The hierarchical clustering 
method is average linkage and the distance metric is Euclidean. A table containing the relative expression values that were used 
in the clustering analysis can be viewed (see Additional File 1).
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Discriminant analysis of the classification power of candi-
date biomarkers
An important next step was to test whether relative expres-
sion data from these samples could be used in a predictive
fashion to classify samples to the appropriate trial arm. In
order to assess this, discriminant analysis [19] of the RT-
PCR data was performed. The relative expression values
from both trials were combined into a single dataset and
then natural log-transformed to reduce the scale of the
values, making control and treated arms more compara-
ble. When the cases were pooled (n = 67) and subjected to
classification prediction, the overall accuracy of assign-
ment to the appropriate trial arm was 84% when lactofer-
rin, CD24, and LCN2 were used as the predictor gene set
(inclusion of MMP-9 slightly reduced the accuracy of
cross-validation). Further cross-validation was performed
by the jackknife method (which does a series of predic-
tions, randomly removing 1 case from the total each
time), and by splitting the data set into 2 random halves
(one a 'training' set and the other a 'testing' set).
The results from each of these steps are summarized in Ta-
ble 5 for a set of 3 of the 4 transcripts that gave the best
accuracy percentage. As indicated, it is predicted that ex-
pression data from these 3 genes would accurately distin-
guish SU5416 arm patients from control arm in 67% to
84% of cases. As a further test, the dataset from the first
clinical trial was used as the 'training' set and the set from
Table 4: Mann-Whitney U Test of relative expression data fromTrial B
Gene n Rank Sum (Treatment) Rank Sum (Control) p-value
(Treatment) (Control)
MMP-9 36 415 251 0.0095
CD24 36 443 223 0.0005
Lactoferrin 36 460 206 0.0001
Lipocalin 2 36 419 247 0.0065
Table 5: Effectiveness of LCN2, CD24, and Lactoferrin as a predictor set for discriminating between the control and SU5416 treatment 
arms.*
1. All cases pooled (67 cases from both trials)
Trial arm Predicted trial arm
Control SU5416 % Correct
Control 26 5 84
SU5416 6 30 83
Total 32 35 84
2. Jackknifed classification matrix for all cases pooled (67 cases from both trials)
Control SU5416 % Correct
Control 26 5 84
SU5416 8 28 78
Total 34 33 81
3. Prediction subset (randomly selected 34 cases) from all cases pooled
Control SU5416 % Correct
Control 13 1 93
SU5416 4 16 80
Total 17 17 85
4. Validation subset (randomly selected 33 cases) from all cases pooled
Control SU5416 % Correct
Control 11 6 65
SU5416 5 11 69
Total 16 17 67
*Cross-validation results are displayed for two different approaches. In section 2, one case is dropped at a time and its group membership predicted 
from the other cases. In sections 3 and 4, cross-validation is carried out by using a randomly selected half of the cases as a training set and the 
remaining half as a test set. Section 4 summarizes the prediction accuracy achieved when the group in section 3 is used as a training set. Note: 
When results of one trial were used in predictive classification of results from the other trial, the accuracy in cross-validation was 86% and 77% for 
the training and testing set, respectively (with a Cohen's kappa value of 0.5507).BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/3
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the second as the 'testing' set, as opposed to pooling the
two trials and randomly selecting cases. In this scenario,
the accuracy in cross-validation was 86% and 77% for the
training and testing set, respectively. This suggests that re-
sults derived from one trial might be applied prospective-
ly in analysis of subsequent similar trials.
Discussion
Large-scale gene expression analysis was applied to blood
RNA samples from a clinical trial of the signal transduc-
tion inhibitor SU5416 to investigate changes in gene ex-
pression that might correlate with exposure to this
experimental cancer therapy. A set of 4 transcripts (CD24,
lactoferrin, LCN2, and MMP-9) was identified, whose ex-
pression was significantly induced at the end of one treat-
ment cycle relative to baseline following SU5416
administration. Discriminant analysis indicated that
changes in expression of these transcripts predicted the tri-
al arm to which a patient belonged with accuracy as high
as 80%.
This work represents a novel approach to clinical biomar-
ker discovery wherein expression profiling of patients'
blood cell RNA is utilized as a surrogate readout of dy-
namic changes occurring in patients bearing solid tumors.
A recent report describes an expression profiling approach
as applied to bone marrow samples before and after
treatment with the tyrosine kinase inhibitor STI-571 in
patients with acute lymphoblastic leukemia [26]. This
work clearly demonstrates utility of the approach in inves-
tigation of drug-resistance development in hematological
malignancies. However, extending similar approaches to
solid tumor oncology is technically and clinically chal-
lenging due to relative inaccessibility of tumor tissue and
difficulties in obtaining samples at multiple time points.
In our investigation, a relatively small number of tran-
script level changes were identified that were specific to
patients receiving an SU5416 dosing regimen, and 4 of
these were independently verified in a larger sample set.
Inter-individual variation and heterogeneity of response
are two variables that have likely impacted this dataset,
and it is possible that a greater number of statistically sig-
nificant changes might be observed if a larger group of pa-
tients were used in the initial Affymetrix analysis. Further,
inclusion of more than a single sampling timepoint after
initiation of treatment would also likely be informative in
future studies, and presumably provide a window to more
acute physiological changes triggered by drug exposure.
Also, a relatively stringent criterion for significance – the
Affymetrix Difference Call – was used in the selection of
transcripts that were expressed differently in each trial
arm. Mining the dataset with other analytical approaches
might lead to a different set of potential biomarkers. How-
ever, it is worth noting that we have retrospectively ap-
plied Significance Analysis of Microarrays, or SAM, [27] to
the Affymetrix dataset: 3 of the 10 most significant genes
identified by that method were among the 4 that were ver-
ified by RT-PCR (LCN2, CD24, and lactoferrin), with
MMP-9 ranked sixteenth. All of the transcripts listed in Ta-
ble 1 were included among the 27 most significant, with
the exception of thrombospondin (ranked 50th).
Independent quantitative RT-PCR verification of initial ar-
ray hybridization results was performed on larger sample
populations obtained from two conceptually similar
Phase III clinical trials that used SU5416. Further explora-
tion of the differential expression data for these 4 tran-
scripts suggests that differences in expression are relatively
robust and adequate to allow classification of patients
into appropriate arms of the trial, with an expected accu-
racy of greater than 70%. It must be stressed that the sub-
ject population size in this qRT-PCR study is not large (n
= 67); however, the results are encouraging given the
challenges of working with samples from these two large
multicenter clinical trials.
These four transcripts are considered to be biomarkers of
the SU5416 administration regimen rather than activity of
SU5416 specifically; with the available samples we could
not exclude the possibility that altered gene expression re-
sulted from exposure to the administration vehicle (Cre-
mophor) or the concomitant premedications
(dexamethasone and H1- and H2-blocker antihistamines)
rather than SU5416. The mouse homologue of one of the
candidate biomarkers, LNC2, has been shown to be regu-
lated at the transcriptional level by dexamethasone in
murine cells [22]. However, there is no published
evidence that the human LCN2 gene is likewise dexame-
thasone-inducible, and there is no description of gluco-
corticoid-responsive elements in the 5' regulatory region
of the human LCN2 gene [28]. Further, preliminary inves-
tigation in our laboratory, using in vitro cultures of puri-
fied PBMCs from healthy volunteers, indicates that
neither the LCN2 gene nor any of the other 3 transcripts is
directly inducible by acute treatment with either SU5416
or dexamethasone (data not shown). The biological con-
nection between expression of these four transcripts and
this therapy regimen remains to be further elucidated.
However, the fact that SU5416 is an inhibitor of VEGF-
mediated angiogenesis may be of relevance to the expres-
sion of MMP-9 mRNA, as the gene encodes a well-charac-
terized enzyme with roles in angiogenesis and tissue
remodeling. Also noteworthy is a report describing bovine
lactoferrin as an inhibitor of VEGF-mediated angiogenesis
in a rat model [29]. Intriguingly, a recent report has
identified a high molecular weight urinary MMP to be a
complex of MMP-9 and LCN2 (herein referred to as neu-
trophil gelatinase-associated lipocalin, or NGAL) proteins
[30]. Such urinary MMP complexes have been described
as useful markers for cancer diagnosis and prognosis. TheBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/3
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relevance of the MMP-9/NGAL protein complex to the ob-
served changes in the levels of their transcripts in blood
cells remains to be determined.
Investigation of expression patterns of these four genes in
samples from clinical trials designed to test other
angiogenesis inhibitors will allow further examination of
their validity as biomarkers of mechanism or drug
exposure. This approach may also be useful in the identi-
fication of biomarkers of clinical response. Our initial
analysis has not yielded a definitive set of gene expression
changes, in PBMC samples, that are correlated with objec-
tive response at end of first cycle; this may be related to a
limited sample size or features of the specific trial design
and patient population. Also, as previously discussed, it
may be essential to profile samples harvested at multiple
time points during the course of therapy in order to fully
capture the variability and extent of dynamic responses
specific to a given therapy. However, the methodology
will be applied to subsequent clinical trials involving oth-
er anti-angiogenesis agents and molecularly targeted
therapeutics.
Additionally and importantly, improvements in reagents
available for storage and purification of RNA from clinical
blood samples should also enhance quality of specimens,
especially in cases where specimens are initially harvested
at multiple clinical sites; the recently introduced PAXgene
blood RNA stabilization reagent is an example of such im-
provement [31]. The analysis of whole blood rather than
purified PBMC as surrogate specimens in future studies
may also minimize variations due to sample handling and
processing. Nevertheless, the results described here dem-
onstrate that human blood samples can serve as surrogate
specimens for biomarker investigations in cancer patients
and imply that large-scale gene expression analysis may be
a useful approach for characterization of drug activity
from clinical trial samples. This expression profiling ap-
proach might also both lead to and be enhanced by im-
provements in oncology trial design, such as more
rational and tailored selection of indications or individu-
als that are most likely to be responsive to a given molec-
ularly targeted therapy.
Conclusions
Large-scale gene expression profiling has been applied to
peripheral blood cells harvested before and after treat-
ment from patients participating in a Phase III clinical tri-
al of SU5416. Four transcripts were identified as potential
biomarkers of SU5416 administration and verified using
a qRT-PCR approach. Discriminant analysis indicated that
expression profiles of these transcripts could be used to
predict the trial arm to which patients belonged. These
results suggest that expression profiling of peripheral
blood cells is a valid surrogate approach for biomarker
discovery in oncology clinical trials.
Competing interests
All authors are employed by SUGEN, Inc.
Authors' contributions
S. DePrimo planned and performed gene expression pro-
filing laboratory work and data analysis, and drafted the
manuscript; L. Wong performed gene expression profiling
laboratory work and aided in clinical sample tracking; D.
Khatry performed statistical data analysis and discrimi-
nant analysis; S. Nicholas performed curation and track-
ing of clinical samples; W. Manning participated in the
supervision and coordination of the study and manu-
script preparation; B. Smolich contributed to the concep-
tion, design and coordination of the study; A.O'Farrell
initiated expression profiling laboratory work and manu-
script preparation and participated in the design, supervi-
sion, and coordination of the study; J. Cherrington
contributed to the conception, design, coordination, and
guidance of the study. All authors read and approved the
final manuscript.
Additional material
Acknowledgements
We would like to thank Helene Yuen and Brian Schryver for technical as-
sistance, Christopher Bauer for guidance in qRT-PCR analyses, and Alyssa 
Morimoto, Mark Jacobs, Sucha Sudarsanam, and Gerard Manning for helpful 
discussions and suggestions.
References
1. Brown PO and Botstein D Exploring the new world of the ge-
nome with DNA microarrays. Nat Genet 1999, 21:33-37
2. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov
JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD and
Lander ES Molecular classification of cancer: class discovery
and class prediction by gene expression monitoring. Science
1999, 286:531-537
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pol-
lack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A,
Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO and
Botstein D Molecular portraits of human breast tumours. Na-
ture 2000, 406:747-752
4. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A,
Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore
T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC,
Greiner TC, Weisenburger DD, Armitage JO, Warnke R and Staudt
LM Distinct types of diffuse large B-cell lymphoma identified
by gene expression profiling. Nature 2000, 403:503-511
Additional file
Additional file 1
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-3-3-S1.pdf]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/3
Page 12 of 12
(page number not for citation purposes)
5. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Pe-
terse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ,
Kerkhoven RM, Roberts C, Linsley PS, Bernards R and Friend SH
Gene expression profiling predicts clinical outcome of breast
cancer. Nature 2002, 415:530-536
6. Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL,
Shaheen RM, Ellis LM, Weitman S, Shawver LK and Cherrington JM
Development of SU a selective small molecule inhibitor of
VEGF receptor tyrosine kinase activity, as an anti-angiogen-
esis agent. Anticancer Drug Des 5416, 15:29-41
7. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana
CD, McConkey DJ, McMahon G and Ellis LM Antiangiogenic ther-
apy targeting the tyrosine kinase receptor for vascular en-
dothelial growth factor receptor inhibits the growth of colon
cancer liver metastasis and induces tumor and endothelial
cell apoptosis. Cancer Res 1999, 59:5412-5416
8. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS,
Mittmann M, Wang C, Kobayashi M, Horton H and Brown EL Ex-
pression monitoring by hybridization to high-density oligo-
nucleotide arrays. Nat Biotechnol 1996, 14:1675-1680
9. Ramanathan M, Weinstock-Guttman B, Nguyen LT, Badgett D, Miller
C, Patrick K, Brownscheidle C and Jacobs L In vivo gene expres-
sion revealed by cDNA arrays: the pattern in relapsing-re-
mitting multiple sclerosis patients compared with normal
subjects. J Neuroimmunol 2001, 116:213-219
10. Rus V, Atamas SP, Shustova V, Luzina IG, Selaru F, Magder LS and Via
CS Expression of cytokine- and chemokine-related genes in
peripheral blood mononuclear cells from lupus patients by
cDNA array. Clin Immunol 2002, 102:283-290
11. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T and Shibuya
M Flt-1, vascular endothelial growth factor receptor 1, is a
novel cell surface marker for the lineage of monocyte-mac-
rophages in humans. Blood 2001, 97:785-791
12. Selheim F, Holmsen H and Vassbotn FS Identification of functional
VEGF receptors on human platelets. FEBS Lett 2002, 512:107-
110
13. Rosen PJ, Amado R, Hecht JR, Chang D, Mulay M, Parson M, Laxa B,
Brown J, Cropp GF, Hannah A and Rosen L A Phase I/II Study of
SU5416 in Combination with 5-FU/Leucovorin in Patients
with Metastatic Colorectal Cancer. Proc Am Soc Clin Oncol 2000,
19:3a (abstract 5D)
14. Rothenberg ML, Berlin JD, Cropp GF, Fleischer AC, Schumaker RD,
Hande KR, Culley A, Dorminy C, Donnelly E, Chen J, Schaaf L and
Hannah AL Phase I/II Study of SU5416 in Combination with Ir-
inotecan/5-FU/LV (IFL) in Patients with Metastatic Colorec-
tal Cancer. Proc Am Soc Clin Oncol 2001, 20:75a (abstract 298)
15. Tripodi D, Lyons S and Davies D Separation of peripheral leuko-
cytes by Ficoll density gradient centrifugation. Transplantation
1971, 11:487-488
16. Chomczynski P A reagent for the single-step simultaneous iso-
lation of RNA, DNA and proteins from cell and tissue
samples. Biotechniques 1993, 15:532-534
17. Eberwine J, Yeh H, Miyashiro K, Cao Y, Nair S, Finnell R, Zettel M and
Coleman P Analysis of gene expression in single live neurons.
Proc Natl Acad Sci U S A 1992, 89:3010-3014
18. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ and Reed
MW  Quantitative reverse transcription-polymerase chain
reaction to study mRNA decay: comparison of endpoint and
real-time methods. Anal Biochem 2000, 285:194-204
19. Huberty CJ Applied Discriminant Analysis New York: Wiley-Interscience
1994, 
20. Nguyen M, Arkell J and Jackson CJ Human endothelial gelatinas-
es and angiogenesis. Int J Biochem Cell Biol 2001, 33:960-970
21. de Fraipont F, Nicholson AC, Feige JJ and Van Meir EG Throm-
bospondins and tumor angiogenesis.  Trends Mol Med 2001,
7:401-407
22. Devireddy LR, Teodoro JG, Richard FA and Green MR Induction of
apoptosis by a secreted lipocalin that is transcriptionally reg-
ulated by IL-3 deprivation. Science 2001, 293:829-834
23. Schneeberger C, Speiser P, Kury F and Zeillinger R Quantitative
detection of reverse transcriptase-PCR products by means
of a novel and sensitive DNA stain. PCR Methods Appl 1995,
4:234-238
24. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Ma-
roun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL
Irinotecan plus fluorouracil and leucovorin for metastatic
colorectal cancer. Irinotecan Study Group. N Engl J Med 2000,
343:905-914
25. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Kara-
sek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and
Rougier P Irinotecan combined with fluorouracil compared
with fluorouracil alone as first-line treatment for metastatic
colorectal cancer: a multicentre randomised trial.  Lancet
2000, 355:1041-1047
26. Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H, Hoelzer D, Ko-
effler HP and Ottmann OG Relation between resistance of
Philadelphia-chromosome-positive acute lymphoblastic leu-
kaemia to the tyrosine kinase inhibitor STI571 and gene-ex-
pression profiles: a gene-expression study.  Lancet 2002,
359:481-486
27. Tusher VG, Tibshirani R and Chu G Significance analysis of
microarrays applied to the ionizing radiation response. Proc
Natl Acad Sci U S A 2001, 98:5116-5121
28. Cowland JB and Borregaard N Molecular characterization and
pattern of tissue expression of the gene for neutrophil gela-
tinase-associated lipocalin from humans. Genomics 1997, 45:17-
23
29. Norrby K, Mattsby-Baltzer I, Innocenti M and Tuneberg S Orally ad-
ministered bovine lactoferrin systemically inhibits
VEGF(165)-mediated angiogenesis in the rat. Int J Cancer 2001,
91:236-240
30. Yan L, Borregaard N, Kjeldsen L and Moses MA The high molecu-
lar weight urinary matrix metalloproteinase (MMP) activity
is a complex of gelatinase B/MMP-9 and neutrophil gelati-
nase-associated lipocalin (NGAL). Modulation of MMP-9 ac-
tivity by NGAL. J Biol Chem 2001, 276:37258-37265
31. Rainen L, Oelmueller U, Jurgensen S, Wyrich R, Ballas C, Schram J,
Herdman C, Bankaitis-Davis D, Nicholls N, Trollinger D and Tryon V
Stabilization of mRNA expression in whole blood samples.
Clin Chem 2002, 48:1883-1890
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/3/3/prepub